Results 171 to 180 of about 299,195 (309)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities. [PDF]

Hum Vaccin Immunother
Adjei-Gati E, Quaye CNO, Lamptey PO, Oklu LD, Kwofie JN, Hafiz YA, Kusi KA.   +6 more
europepmc   +1 more source

Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.

Journal of Hepatology, 2017
S. Lemon, J. J. Ott, P. van Damme, D. Shouval   +3 more
semanticscholar   +1 more source

Natural an dartificial protein cages : design, structure and therapeutic applications [PDF]

, 2017
Chakraborti, Soumyananda, Heddle, Jonathan, Iwasaki, Kenji   +2 more
core   +1 more source

Association Between Polymorphisms rs11003125 and rs7096206 of the MBL2 Gene and the Stages of Hepatitis B Progression in Burkina Faso: A Comparative Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Objectives Hepatitis B virus (HBV) infection remains a major global health burden, with disease progression influenced by host genetic and immune factors, including variants in the mannose‐binding lectin 2 (MBL2) gene. This study aimed to evaluate the association between MBL2 polymorphisms and clinical outcomes of HBV infection ...
Minane Nafissa Triande, Lassina Traore, Sidnooma Véronique Zongo, Teega‐Wendé Clarisse Ouedraogo, Mousso Savadogo, Sanata Nadine Kiemde, Tegwindé Rébéca Compaore, Augustin Tozoula Bambara, Roger Arsène Sombie, Patoinewendé Denise Ilboudo, Albert Théophane Yonli, Bolni Marius Nagalo, Florencia Wendkuuni Djigma, Jacques Simpore   +13 more
wiley   +1 more source

Whispers of Pathogens; Social Contagion in Infectious Disease Dynamics: A Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Infectious disease dynamics are deeply intertwined with social structures, behaviors, and information systems. This narrative review examines how social factors conceptualized through the integrated lens of “social contagion” within a syndemic framework shape infectious disease patterns from January 2000 to January 2024 ...
Sayed Mortaza Fayez
wiley   +1 more source

Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps. [PDF]

Vaccines (Basel)
Batbold E, Dashdorj N, Zoulim F, Bartosch B.   +3 more
europepmc   +1 more source

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo, Alan Y. Hsu, De‐Yi Liu, Bing‐Qi Wu, James Cheng‐Chung Wei, Ning‐Yi Hsia, Yi‐Ching Shao, Chun‐Ting Lai, Chun‐Chi Chiang, Chun‐Ju Lin, Huan‐Sheng Chen, Yu‐Hsun Wang, Hsin Tseng, Ho‐Che Hsu, Yi‐Yu Tsai   +14 more
wiley   +1 more source

Hepatitis B vaccination at birth: science, myths, and the safety net imperative. [PDF]

Front Immunol
Gupta RK.
europepmc   +1 more source

Predicting optimal impact interventions in the post‐HPV vaccination world

International Journal of Cancer, Volume 158, Issue 9, Page 2262-2271, 1 May 2026.
Abstract Prophylactic vaccination is a powerful tool that changes exposure to infections and associated morbidity of preventable diseases. We discuss the impact of pneumococci and human papillomavirus (HPV) vaccination on the population biology of the two micro‐organisms and related public health effects.
Matti Lehtinen, Marc Lipsitch, Ville N. Pimenoff, Karin Sundström, Johannes Berkhof, Iacopo Baussano, Simopekka Vänskä, Joakim Dillner   +7 more
wiley   +1 more source